NANO-X IMAGING LTD. announced results for Q3 2025, with $3.4 million revenue compared to $3.0 million in Q3 2024. Recent highlights include entering new commercial collaborations and acquiring Vaso Healthcare IT. The company reported a net loss of $13.7 million for Q3 2025. They anticipate over 100 units deployed globally by year-end 2025, with a 2026 revenue target of $35 million. The Company had total cash, cash equivalents, deposits, and securities of $55.5 million as of September 30, 2025. They also reported property, equipment, and intangible assets. Shareholders’ equity stood at $156.7 million with 65.4 million shares outstanding as of the same date.

The Company also provided non-GAAP financial measures, adjusting for items like amortization of intangible assets and share-based compensation. Non-GAAP net loss attributable to ordinary shares for Q3 2025 was $9.9 million. Non-GAAP cost of revenue was $10.7 million, non-GAAP gross profit (loss) was ($1.4) million, and non-GAAP gross profit margin was (15%). Non-GAAP research and development expenses were $13.4 million, non-GAAP sales and marketing expenses were $3.1 million, and non-GAAP general and administrative expenses were $13.6 million.

The Company will host a conference call and webcast on November 20, 2025, to discuss the results and business update. Individuals can register online to participate. Nanox is focused on driving preventive healthcare through affordable medical imaging technologies and AI. Their vision is to improve early detection and treatment globally. For more information, visit www.nanox.vision.

Read more at GlobeNewswire: Nanox Announces Third Quarter of 2025 Financial Results and